MAP2K7 and glioblastoma: As the extensive crossover of the MAPK and PI3K/AKT/mTOR signalling cascades have been described thus far, it is no wonder that targeting broad effector molecules such as AKT, mTOR, or BRAF/MEK have proven difficult as a treatment strategy in glioblastoma.